Current and Emerging Biologics for Atopic Dermatitis - 08/10/24

Doi : 10.1016/j.iac.2024.08.001

Michael Nevid, MD ^a, Mark Boguniewicz, MD ^b,^⁎
^a Division of Allergy-Immunology, Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, 1400 Jackson Street, J312, Denver, CO 80206, USA
^b Division of Allergy-Immunology, Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, 1400 Jackson Street, J310, Denver, CO 80206, USA

^∗Corresponding author.

Résumé

Atopic dermatitis (AD) is a common chronic pruritic inflammatory skin disease that affects all ages and is recognized as a global health problem. Pathophysiology is complex with skin barrier abnormalities, immune dysregulation, and microbial dysbiosis all implicated. Markers of immune and inflammatory activation in the circulation provide a rationale for systemic therapy. Type 2 immune polarization is central, though other cytokine pathways including Th22 and Th17/IL-23 have been described, suggesting additional therapeutic targets in a subset of patients. Dupilumab and tralokinumab are monoclonal antibodies currently approved for moderate-to-severe AD with lebrikizumab and nemolizumab in late stages of development.

Le texte complet de cet article est disponible en PDF.

Keywords : Atopic dermatitis, Eczema, Biologics, Monoclonal antibody, Dupilumab, Tralokinumab, Lebrikizumab, Nemolizumab